"My argument to Mehmet Oz is that if you want to protect Medicare costs in 10 years, have [the Affordable Care Act] and Medicare plans list these drugs now," Ricks said to Bloomberg. "We know so much about how much cost savings there will be downstream in heart disease and other conditions." This statement emphasizes the potential long-term benefits of covering GLP-1 drugs for managing obesity, highlighting a proactive approach to healthcare costs.
The CBO estimated that the direct cost of Medicare coverage for anti-obesity drugs between 2026 and 2034 would be nearly $39 billion, while the savings from improved health would total just a little over $3 billion, for a net cost to US taxpayers of about $35.5 billion. This insight from the CBO contrasts the hopes of the drug manufacturers with the reality of the financial impact on taxpayers.
Collection
[
|
...
]